UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

SY M BO L: BS G M 1 20th Annual Needham Virtual Healthcare Conference NASDAQ : BSGM | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

SY M BO L: BS G M 1 Benzinga Biotech Small Cap Conference March 2021 NASDAQ : BSGM | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 Commission File Number 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 54 Wilton Road, 2nd Floor Westport, CT 06880 (203) 409-5444 (Address o ...

S Y M BOL: BSG M 1 Sidoti Winter 2021 Investor Conference January 13th – 14th, 2021 NASDAQ : BSGM | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Summary of BioSig Technologies, Inc. Business Development Update Conference Call Company Overview - **Company**: BioSig Technologies, Inc. (OTCQB: BSGM) - **Date of Call**: November 18, 2020 - **Participants**: - Ken Londoner - Chairman and CEO - Andy Ballou - Vice President of Investor Relations - Other participants from Laidlaw & Company, Plum Tree Consulting, and JJK Consulting Key Points Industry and Business Updates - **Core Business**: Focus on the PURE EP System installations and commercialization outlook [4][12] - **ViralClear Subsidiary**: - Phase 2 clinical trial for merimepodib halted based on Safety Monitoring Committee's recommendation [7] - Operations winding down, with cash proceeds redirected to NeuroClear neuro technology program [9][11] - Engaging with three pharmaceutical/biotech companies for potential partnerships [10] Financial Performance - **Cash Position**: $32.7 million on the balance sheet, sufficient to support operations through 2021 and into 2022 [24] - **Burn Rate**: Approximately $1.4 million per month for the PURE EP business, with a total burn of $6.2 million in Q3 2020 [24][29] - **Commercial Inventory**: 65 units of commercial inventory already paid for, expected to generate revenue over the next 12 months [25] PURE EP System Progress - **Installations**: - Total of six installations completed, with plans for two additional installations [12][15] - Positive feedback from physicians using the system, with 363 total procedures performed year-to-date [13][14] - **Clinical Data**: - 35.5% of cases showed BioSig signals had more visible components compared to traditional systems [17] - Ongoing collection of clinical data to support future studies and marketing efforts [19][66] Market Strategy and Future Plans - **Expansion Plans**: - Targeting 12 to 16 hospitals for limited market release, with a focus on Northeast, Florida, and Texas regions in 2021 [20][21] - Plans to recruit additional sales and marketing personnel to support expansion [21] - **Commercial Transactions**: Expecting first commercial transaction in Q4 2020, with visibility for more based on successful installations [22] Challenges and Considerations - **COVID-19 Impact**: The pandemic has affected installation timelines, with some installations pushed to Q1 2021 [15][49] - **ViralClear Investments**: Investors in ViralClear will hold a stake in the NeuroClear program as the company seeks to create value from these assets [52] Additional Insights - **User Feedback**: Positive user feedback has led to software upgrades planned for early 2021 [33] - **Revenue Model**: Revenue will be generated from hardware sales, service contracts, and software upgrades [56][60] - **Clinical Trials**: Plans for investigator-initiated clinical trials to further validate the efficacy of the PURE EP system [66] Conclusion - BioSig Technologies is making significant progress in the commercialization of its PURE EP System, with a strong financial position and positive feedback from early adopters. The company is strategically planning for expansion and is optimistic about future growth despite challenges posed by the COVID-19 pandemic.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...